CSL · Company research
Carlisle Companies, Inc. (CSL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
28records availableBasic Materials
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| CSL stock trades 3.73 percent above its EUR 113.10 target - ad-hoc-news.de | CSL stock trades 3.73 percent above its EUR 113.10 target ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 16, 2026 | neutral | 0 | 0.6 |
| CSL agrees USD 1.6 billion Alentis deal. CSL stock sits 13.61 percent below its high - ad-hoc-news.de | CSL agrees USD 1.6 billion Alentis deal. CSL stock sits 13.61 percent below its high ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 16, 2026 | neutral | 0 | 0.6 |
| 14,212 Carlisle Companies Incorporated $CSL Shares Sold by Formuepleje A S - MarketBeat | 14,212 Carlisle Companies Incorporated $CSL Shares Sold by Formuepleje A S MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| MMM Q3 Earnings on Deck: How to Approach the Stock Now? | 3M is expected to report Q3 2026 revenue of $6.60 billion and EPS of $2.41 on October 20. The company's Safety and Industrial and Transportation and Electronics segments are expected to perform well, supported by restructuring efforts. However, weakness in the Consumer segment and elevated R&D costs pose challenges. The stock trades at a premium valuation compared to industry peers. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.333 | 1 |
| MMM Q3 Earnings on Deck: How to Approach the Stock Now? | 3M is expected to report Q3 2026 revenue of $6.60 billion and EPS of $2.41 on October 20. The company's Safety and Industrial and Transportation and Electronics segments are expected to perform well, supported by restructuring efforts. However, weakness in the Consumer segment and elevated R&D costs pose challenges. The stock trades at a premium valuation compared to industry peers. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.333 | 1 |
| Carlisle Companies Incorporated (NYSE:CSL) Stock Has Consensus Target Price of $394.50 - MarketBeat | Carlisle Companies Incorporated (NYSE:CSL) Stock Has Consensus Target Price of $394.50 MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| Carlisle Companies Incorporated (CSL) Stock Forecasts - Yahoo Finance | Carlisle Companies Incorporated (CSL) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| CSL Mar 2027 410.000 call (CSL270319C00410000) Interactive Stock Chart - Yahoo! Finance Canada | CSL Mar 2027 410.000 call (CSL270319C00410000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| Lixudebart Deal Could Be A Game Changer For CSL (ASX:CSL) - Simply Wall Street | Lixudebart Deal Could Be A Game Changer For CSL (ASX:CSL) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| Carlisle Companies (NYSE:CSL) Stock Price Target Cut by Robert W. Baird - MarketBeat | Carlisle Companies (NYSE:CSL) Stock Price Target Cut by Robert W. Baird MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| CSL Oct 2026 370.000 call (CSL261016C00370000) Stock Price, News, Quote & History - Yahoo! Finance Canada | CSL Oct 2026 370.000 call (CSL261016C00370000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| Responsive Playbooks and the CSL Inflection - Stock Traders Daily | Responsive Playbooks and the CSL Inflection Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 9, 2026 | neutral | 0 | 0.6 |
| Carlisle Exhibits Strong Prospects Despite Persisting Headwinds | Carlisle Companies (CSL) reported 8% revenue growth in its Construction Materials segment and 10% growth in Weatherproofing Technologies in Q2 2026, driven by strong re-roofing demand and market-share gains. However, elevated petroleum-based raw material and freight costs, exacerbated by Middle East geopolitical tensions, pressured margins as cost of sales increased 10.3%. The company raised its share repurchase target to $1.2 billion and increased its quarterly dividend by 14%, marking its 50th consecutive annual dividend increase. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Carlisle Exhibits Strong Prospects Despite Persisting Headwinds | Carlisle Companies (CSL) reported 8% revenue growth in its Construction Materials segment and 10% growth in Weatherproofing Technologies in Q2 2026, driven by strong re-roofing demand and market-share gains. However, elevated petroleum-based raw material and freight costs, exacerbated by Middle East geopolitical tensions, pressured margins as cost of sales increased 10.3%. The company raised its share repurchase target to $1.2 billion and increased its quarterly dividend by 14%, marking its 50th consecutive annual dividend increase. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Diversified Management Inc. Acquires New Holdings in Carlisle Companies Incorporated $CSL - MarketBeat | Diversified Management Inc. Acquires New Holdings in Carlisle Companies Incorporated $CSL MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Jumps 17% on CSL Rollout. How Much Revenue Could It Add? - EBC Financial Group | Haemonetics Stock Jumps 17% on CSL Rollout. How Much Revenue Could It Add? EBC Financial Group | View source ↗ | EBC Financial Group | Oct 9, 2026 | neutral | 0 | 0.6 |
| Haemonetics advances 17% on CSL supply deal (HAE:NYSE) - Seeking Alpha | Haemonetics advances 17% on CSL supply deal (HAE:NYSE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside - StocksToTrade | Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside StocksToTrade | View source ↗ | StocksToTrade | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics Stock Hits 52-Week High - Here's Why - TradingView | Haemonetics Stock Hits 52-Week High - Here's Why TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| Will MMM's Safety & Industrial Segment Remain a Core Strength in 2026? | 3M Company reported strong Q2 2026 performance with its Safety and Industrial segment posting broad-based growth. Industrial adhesives and tapes sales rose 13%, personal safety increased 9.4%, and organic sales grew 8.2%. The company provided an upbeat 2026 outlook with adjusted organic sales expected to grow over 3.5% and adjusted earnings projected between $8.80-$8.95 per share. Peer Honeywell faced softness in its Process Automation segment, while Carlisle Companies showed strength in Construction Materials. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.333 | 1 |
| Will MMM's Safety & Industrial Segment Remain a Core Strength in 2026? | 3M Company reported strong Q2 2026 performance with its Safety and Industrial segment posting broad-based growth. Industrial adhesives and tapes sales rose 13%, personal safety increased 9.4%, and organic sales grew 8.2%. The company provided an upbeat 2026 outlook with adjusted organic sales expected to grow over 3.5% and adjusted earnings projected between $8.80-$8.95 per share. Peer Honeywell faced softness in its Process Automation segment, while Carlisle Companies showed strength in Construction Materials. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.333 | 1 |
| Will MMM's Safety & Industrial Segment Remain a Core Strength in 2026? | 3M Company reported strong Q2 2026 performance with its Safety and Industrial segment posting broad-based growth. Industrial adhesives and tapes sales rose 13%, personal safety increased 9.4%, and organic sales grew 8.2%. The company provided an upbeat 2026 outlook with adjusted organic sales expected to grow over 3.5% and adjusted earnings projected between $8.80-$8.95 per share. Peer Honeywell faced softness in its Process Automation segment, while Carlisle Companies showed strength in Construction Materials. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.333 | 1 |
| Haemonetics stock surges 17% on CSL Plasma supply deal update - Investing.com | Haemonetics stock surges 17% on CSL Plasma supply deal update Investing.com | View source ↗ | Investing.com | Oct 8, 2026 | neutral | 0 | 0.6 |
| Haemonetics stock jumps on CSL Plasma device rollout plan - StreetInsider | Haemonetics stock jumps on CSL Plasma device rollout plan StreetInsider | View source ↗ | StreetInsider | Oct 8, 2026 | neutral | 0 | 0.6 |
| Carlisle Companies Incorporated (CSL) Stock Forecasts - Yahoo Finance | Carlisle Companies Incorporated (CSL) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somnivera - Pharmaceutical Executive | Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somnivera Pharmaceutical Executive | View source ↗ | Pharmaceutical Executive | Oct 6, 2026 | neutral | 0 | 0.6 |
| CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - KSL News | CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis KSL News | View source ↗ | KSL News | Oct 5, 2026 | neutral | 0 | 0.6 |
| CSL shares up 17% as immunoglobulin boost points to signs of recovery - Fierce Pharma | CSL shares up 17% as immunoglobulin boost points to signs of recovery Fierce Pharma | View source ↗ | Fierce Pharma | Aug 18, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.